Dupixent

Scratching the surface of the urticaria pipeline
Scratching the surface of the urticaria pipeline
EP Vantage
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Flag link:
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Medical Marketing and Media
Dupixent
Sanofi
Regeneron
Flag link:
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Fierce Biotech
Aslan
Dupixent
Japan
eczema
Sanofi
Regeneron
eblasakimab
Flag link:
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Medical Marketing and Media
Dupixent
Sanofi
Regeneron
DTC advertising
Flag link:
Sanofi, Regeneron flesh out COPD data with Dupixent
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Sanofi
Regeneron
COPD
Dupixent
Flag link:
Revolo drops dab of midphase data on would-be Dupixent rival
Revolo drops dab of midphase data on would-be Dupixent rival
Fierce Biotech
Revolo Biotherapeutics
clinical trials
allergies
Dupixent
Flag link:
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
Sanofi and Regeneron face a high-risk test for Dupixent
Sanofi and Regeneron face a high-risk test for Dupixent
EP Vantage
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
Dupixent kicks off 2023 as top pharma brand for ad impressions
Dupixent kicks off 2023 as top pharma brand for ad impressions
Medical Devices and Diagnostics Industry
Sanofi
Dupixent
asthma
pharma advertising
Flag link:
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Fierce Pharma
Sanofi
Dupixent
earnings
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
JPM23: Sanofi has reached the 'steady state' Paul Hudson envisioned years ago, CEO says
JPM23: Sanofi has reached the 'steady state' Paul Hudson envisioned years ago, CEO says
Fierce Pharma
JPMHC 2023
Sanofi
Paul Hudson
Pharma CEOs
Dupixent
Flag link:
What This Drug News Could Mean for Sanofi Shareholders
What This Drug News Could Mean for Sanofi Shareholders
Motley Fool
Sanofi
Dupixent
Flag link:
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent
Fierce Pharma
Regeneron
Sanofi
Dupixent
UK
side effects
Flag link:
Dupixent nears EU approval for rare skin disease prurigo nodularis
Dupixent nears EU approval for rare skin disease prurigo nodularis
Pharmaphorum
Sanofi
Regeneron
Dupixent
Europe
prurigo nodularis
Flag link:
Sanofi sees faster profit growth on Dupixent, flu vaccine demand
Sanofi sees faster profit growth on Dupixent, flu vaccine demand
Yahoo/Reuters
Sanofi
earnings
Dupixent
vaccines
Flag link:
Dupixent Shows Promise as First Treatment for Childhood EoE
Dupixent Shows Promise as First Treatment for Childhood EoE
BioSpace
Dupixent
Sanofi
Regeneron
pediatric
clinical trials
eosinophilic esophagitis
Flag link:
FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis
FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis
Pharmaceutical Business Review
Sanofi
Regeneron
Dupixent
prurigo nodularis
FDA
Flag link:

Pages